• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Asparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in < em > KRAS < /em > mutant colorectal cancer
bioRxiv. 2023 May 5:2023.05.05.539577. doi: 10.1101/2023.05.05.539577. Preprint.ABSTRACTThe nutrient status of the tumor microenvironment has major impacts on cell growth. Under nutrient depletion, asparagine synthetase (ASNS)-mediated asparagine production increases to sustain cell survival. G protein-coupled estrogen receptor-1 (GPER1) signaling converges via cAMP/PI3K/AKT with KRAS signaling to regulate ASNS expression. However, the role of GPER1 in CRC progression is still debated, and the effect of nutrient supply on both ASNS and GPER1 relative to KRAS genotype is not well understood. Here, we modeled a restricted nu...
Source: Cancer Control - May 19, 2023 Category: Cancer & Oncology Authors: Lingeng Lu Qian Zhang Xinyi Shen Pinyi Zhen Audrey Marin Rolando Garcia- Milian Jatin Roper Sajid A Khan Caroline H Johnson Source Type: research

Anti-PD-L1 Antibody and/or 17 β-estradiol Treatment Induces Changes in The Gut microbiome in MC38 Colon Tumor Model
CONCLUSION: Our results suggest that gut microbial changes induced by the pretreatment of estrogen before anti PD-L1 might contribute to treatment of MC38 colon cancer.PMID:36634616 | DOI:10.4143/crt.2022.1427
Source: Cancer Control - January 12, 2023 Category: Cancer & Oncology Authors: Chin-Hee Hong Nayoung Kim Ryoung Hee Nam Soo In Choi Jae Young Jang Jina Choi Ha-Na Lee Source Type: research

Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development
Cancer J. 2022 May-Jun 01;28(3):196-203. doi: 10.1097/PPO.0000000000000598.ABSTRACTSeveral formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure bo...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Abbie J Laing Louise Newson James A Simon Source Type: research

Pages: 1  2  3  4